Business Description
Otofarma SpA
ISIN : IT0005663361
Description
Otofarma SpA is engaged in the construction and production of hearing aids, is constantly growing in the audiological field to provide adequate responses to every type of hearing aid need to its customers who require the possible personalized application of custom-made hearing aids. It provides otoacoustic medical devices and TELEMEDICINE services exclusively in affiliated pharmacies, possessing a portfolio of Instrumental IT patents.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.88 | |||||
Equity-to-Asset | 0.5 | |||||
Debt-to-Equity | 0.57 | |||||
Debt-to-EBITDA | 1.25 | |||||
Interest Coverage | 7.62 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 29.03 | |||||
9-Day RSI | 24.04 | |||||
14-Day RSI | 22.95 | |||||
3-1 Month Momentum % | -21.78 | |||||
6-1 Month Momentum % | -30.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.11 | |||||
Quick Ratio | 2.07 | |||||
Cash Ratio | 0.76 | |||||
Days Inventory | 37.32 | |||||
Days Sales Outstanding | 83.67 | |||||
Days Payable | 317.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 88.55 | |||||
Operating Margin % | 12.73 | |||||
Net Margin % | 4.59 | |||||
EBITDA Margin % | 15.16 | |||||
FCF Margin % | 13.28 | |||||
OCF Margin % | 19.26 | |||||
ROE % | 16.7 | |||||
ROA % | 7.59 | |||||
ROIC % | 13.38 | |||||
ROC (Joel Greenblatt) % | 50.51 | |||||
ROCE % | 33.56 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 23.14 | |||||
PE Ratio without NRI | 23.14 | |||||
PS Ratio | 1.06 | |||||
PB Ratio | 3.17 | |||||
Price-to-Tangible-Book | 4.59 | |||||
Price-to-Free-Cash-Flow | 7.98 | |||||
Price-to-Operating-Cash-Flow | 5.51 | |||||
EV-to-EBIT | 8.8 | |||||
EV-to-EBITDA | 7.38 | |||||
EV-to-Revenue | 1.12 | |||||
EV-to-FCF | 8.44 | |||||
Price-to-Graham-Number | 2.19 | |||||
| Price-to-Net-Current-Asset-Value | 8.48 | |||||
Earnings Yield (Greenblatt) % | 11.36 | |||||
FCF Yield % | 12.12 |
GF Valueâ„¢
Otofarma SpA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Otofarma SpA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Otofarma SpA
No articles.